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To study the basis of cellular latency of human immunodeficiency virus (HIV), we have used a recombinant
luciferase-encoding HIV (HXB-Luc) to superinfect nonproductively HIV-1-infected human leukemic cell lines.
HXB-Luc contains the Photinus pyralis luciferase gene in place of the nef gene and provides a highly sensitive,
simple assay for HIV infection and expression. To circumvent any superinfection block in latently infected cells,
we also generated viruses pseudotyped with murine leukemia virus amphotropic envelope (HXB-Luc:ampho).
The parental uninfected lines, U937 and A3.01, from which the latently infected cell lines Ul and ACH-2,
respectively, were derived could be readily infected with pseudotyped or nonpseudotyped reporter viruses.
However, superinfection of Ul cells with either HXB-Luc or HXB-Luc:ampho resulted in only low levels of
luciferase activity. Like the endogenous provirus, HXB-Luc provirus could be efficiently activated by phorbol
ester treatment of HXB-Luc:ampho-superinfected Ul cells. In contrast, superinfection of ACH-2 cells resulted
in active expression of the secondarily introduced virus even in unstimulated cells and luciferase production
higher than in the parental cell line A3.01. Thus, the proviral latency in Ul cells appears to result from a defect
in the cellular environment (a trans effect), whereas the latency in ACH-2 is specific to the integrated provirus
and is probably a cis effect due to the site of integration. These results demonstrate distinct modes of proviral
latency in these two cell line models and may have implications in our understanding of the regulation and
significance of cellular latency in HIV infection.
Acute infection of some human leukemic cell lines with
human immunodeficiency virus (HIV) generates a cytopathic
infection which leaves behind a heterogeneous population of
chronically infected survivors (5, 14, 17). A number of cell lines
have been derived from such chronically HIV-infected cells
(7); a few of these have been found to have low basal
expression of virus yet retain the ability to produce large
quantities of infectious virus when stimulated (14, 16). These
cell lines have been studied extensively as in vitro models for
cellular latency. U1 is one such cell line that was cloned from
the chronically infected promonocytic leukemic cell line U937,
and ACH-2 was similarly derived from the T-lymphocytic
leukemic cell line A3.01. Studies of Ul and ACH-2 have
provided substantial information about the stimuli and regu-
latory pathways that may be involved in the activation of HIV
replication in vivo.
In both the Ul and ACH-2 cell lines, infectious virus
production can be induced with phorbol ester or specific
cytokines such as tumor necrosis factor alpha (15-17, 34). This
activation results in a large induction of HIV mRNA, a process
believed to involve, at least in part, the action of transcription
factor NF-KB (10, 19). Both cell lines have been found to
express only low levels of predominantly multiply spliced HIV
mRNA in the unstimulated state. Activated HIV gene expres-
sion results in an increase in the amounts of multiply spliced
mRNA and the viral regulatory proteins which they encode
(28, 33), including Rev, whose function is critical for subse-
quent expression of unspliced and singly spliced mRNAs which
encode HIV structural proteins (26, 27, 32). In this regard, the
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sequence of events which follows activation of latent HIV in
Ul and ACH-2 resembles the events that follow integration
during acute infection (22).
Despite the increased understanding of the mechanisms
involved in proviral activation in these latently infected lines,
the underlying cause of their low basal HIV-specific transcrip-
tion is not well understood. Because infectious virus can be
obtained from both cell lines, it is unlikely that defective
proviruses are the cause of low basal expression. Therefore, it
is possible that their intracellular environments differ from
the parental cell lines U937 and A3.01, such that viral repli-
cation cannot occur efficiently in the unstimulated state.
Alternatively, low basal expression of the latent provirus could
be due to a suboptimal site(s) of integration. Recently, the
latter mechanism has been suggested for the ACH-2 cell line
(41).
To directly address these questions we have constructed a
reporter HIV-1 with the Photinus pyralis luciferase gene (9)
cloned in place of the nef gene and examined the ability of Ul,
ACH-2, and their parental cell lines to support viral expression
by measuring luciferase activity produced by the reporter virus
on infection. Luciferase gene expression thus provides a highly
sensitive, quantitative marker for HIV expression. The nef
gene was chosen as the site for reporter gene insertion by
virtue of its property of being expressed in a Rev-independent
manner (23) and because it is known to be nonessential for in
vitro infection (13, 40). To overcome a possible block to HIV
superinfection in these chronically infected cells, we used
reporter virus pseudotyped with murine leukemia virus
(MuLV) amphotropic envelope (24, 25) in addition to non-
pseudotyped reporter virus.
Superinfection of the Ul cells with the luciferase reporter
virus has revealed a cellular environment that does not support
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expression of an additional HIV provirus. In contrast, we find
that ACH-2 displays no such block to expression of the
luciferase reporter. Our studies have thus revealed two distinct
mechanisms of proviral latency in these nonproductively in-
fected cell lines.
MATERIALS AND METHODS
Cell lines and plasmids. The luciferase reporter virus was
derived from molecular clone R73 (provided by Mark Fein-
berg, The Gladstone Institute of Virology and Immunology,
San Francisco, Calif.), a derivative of the HXB-2D isolate (38).
A proviral construct with a deletion in nef, pHXBAnef, was
first constructed by introducing a NotI site into the 5' region of
the nefgene of R73 by using PCR as follows. A 5' primer which
overlaps with a unique BamHI site and a 3' primer which
places NotI and XhoI sites at the 5' end of the nef coding
region were used. The resulting clone contains a deletion of
the region encoding the first 34 amino acids of the nef gene.
The P. pyralis luciferase gene was subsequently cloned between
the NotI and XhoI sites of pHXBAnef. The resulting proviral
plasmid, pHXB-Luc, carries an inserted luciferase gene which
utilizes the natural Nef translation start site. An envelope
mutant variant, HXB-LucE-, was created by the ablation of
an NdeI site in the 5' region of the env gene. Identical
constructs were produced in the context of proviral clone NL43
(1) by cloning the BamHI-XhoI fragment from HXB-Luc into
corresponding sites in NL43. NL43 is a fusion of the proviral
DNA from the NY5 isolate and the LAV-1 isolate (1).
Cell lines Ul, ACH-2, U937, and A3.01 were obtained from
Tom Folks through the AIDS Reference and Reagent Pro-
gram. HOST4 cells and amphotropic envelope expression
vector pSVL-MEA (24) were generous gifts from Ned Landau,
Aaron Diamond AIDS Research Center, New York, N.Y.
Nonadherent cell lines were grown in RPMI 1640 medium
containing 10% (vol/vol) fetal calf serum, penicillin, and
streptomycin. Adherent cell lines 293, COS, HOS, and HOST4
were grown in Dulbecco's modified Eagle's medium containing
10% fetal calf serum.
Transfection, infection, and luciferase assays. Virus was
produced by transfection of proviral DNA into the human
embryonic kidney cell line, 293, or African green monkey
kidney cell line, COS, by using a modified calcium phosphate
method (31). Pseudotyped virus was similarly produced by
cotransfection of reporter virus DNA with an expression vector
for MuLV amphotropic envelope, pSVL-MEA. The medium
was changed 18 to 24 h after transfection, and supernatants
were harvested 2 days after transfection. Virus-containing
supernatants were cleared of cellular debris by centrifugation
at 500 x g for 5 min. Supernatant p24 was determined by
antigen capture assay (Abbott Laboratories) to quantitate the
virion content. Target cells of interest were infected for 1 to 2
h at 37°C with indicated amounts of p24 at a concentration of
2 x 106 to 4 x 106 cells per ml in the presence of 8 ,ug of
Polybrene per ml. The cells were then washed with phosphate-
buffered saline and resuspended to a concentration of 2.5 x
105 cells per ml in fresh medium immediately following the
incubation. Cells (1 x 106 to 2 x 106) harvested at the
indicated times postinfection were lysed with 100 RI of 1 x
luciferase lysis buffer (Promega). A 10-,I sample of each lysate
was assayed for photon emission with a luminometer (Opto-
compl) by using the Promega Luciferase Assay System. Pro-
tein content in the cell lysates was determined by using the
Bio-Rad protein assay reagent as specified by the manufac-
turer.
Quantitative PCR. Infected cells were harvested at 72 h
postinfection, and genomic DNAs were prepared as previously
described (2). DNAs were standardized by measuring UV
A260, and the integrity of samples was confirmed by visualiza-
tion with ethidium bromide stain on agarose gel. Reactions
were performed in a 50-,A volume containing 500 ng of cellular
DNA, 100 ng each of luciferase PCR primers (5'-CAG AAT
CGT CGT ATG CAG TGA-3' and 5'-CTA CGG TAG GCT
GCG AAA TGT-3'), 50 ,uM each deoxynucleoside triphos-
phate, 16.6 nM [at-32P]dCTP (2.5 jCi), 1.5 mM MgCl2, 50 mM
KCl, 10 mM Tris-HCl (pH 7.9), and 1.25 U of Taq polymerase
(Boehringer Mannheim). PCR cycles consisting of 94°C for 60
s and 66°C for 90 s for 27 rounds were used.
RESULTS
To investigate the cause of low basal viral expression in the
latently infected human leukemic cell lines, Ul and ACH-2, we
engineered an infectious HIV proviral construct with the firefly
luciferase gene cloned into the region which encodes the viral
regulatory gene, nef (see Materials and Methods). The result-
ing virus, HXB-Luc, expresses luciferase upon infection and
allows for highly sensitive, quantitative measurement of HIV
gene expression. When pseudotyped with MuLV amphotropic
envelope, the luciferase-encoding virus should overcome any
superinfection block present in the latently infected cell lines,
allowing for characterization of HIV expression in Ul and
ACH-2 relative to the expression observed in their respective
parental cell lines.
Luciferase-encoding HIV-1 pseudotyped with amphotropic
envelope can infect cells independently of CD4 expression. To
create an infectious luciferase-encoding pseudotyped virus
(HXB-Luc:ampho), COS cells were cotransfected with the
expression vector for the MuLV amphotropic envelope, pSVL-
MEA, and luciferase-encoding proviral DNA, pHXB-Luc.
Nonpseudotyped virus was similarly produced by transfection
of the pHXB-Luc provirus alone. Fivefold dilutions of the
supernatants from the transfected cells were used to infect
human osteosarcoma (HOS) cells or the stably CD4-expressing
HOS derivative, HOST4. Cells were harvested and tested for
luciferase activity 48 h postinfection. As expected, the non-
pseudotyped virus was unable to efficiently infect the CD4-
negative HOS cells (Fig. 1). However, HXB-Luc-infected HOS
cells did express minimal luciferase activity above background
when infected with the highest concentration of virus tested
(corresponding to approximately 10 ng of p24), indicating that
very-low-level infection may occur in HOS cells that do not
express CD4. In contrast, the HXB-Luc virus gave rise to
abundant luciferase activity when used to infect the CD4-
positive cell line, HOST4. When provided with the MuLV
amphotropic envelope, HIV was able to efficiently infect both
CD4- HOS cells and CD4+ HOST4. Thus, as described
previously (24, 25), the amphotropic envelope confers CD4
independence for HIV infection of human cells. In all infec-
tions, the observed luciferase activity was roughly proportional
to the level of input p24, with fivefold dilutions resulting in
corresponding decreases in luciferase activity.
Proviral latency in the Ul monocytic line is due to a cellular
phenotype which does not support basal expression of HIV. To
test whether the latently infected Ul cells could support the
expression of an added HIV provirus, we infected the Ul cell
line and its parental line, U937, with nonpseudotyped virus,
HXB-Luc, and pseudotyped virus, HXB-Luc:ampho. Approx-
imately one million cells were harvested at various times
postinfection and assayed for luciferase activity. When super-
infected with nonpseudotyped HXB-Luc virus, latently in-
fected Ul cells expressed only low levels of luciferase activity
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1ooooooo the differences in expression of the luciferase-encoding virus in
Ul and U937 cells were due to a greater efficiency of viral
E 0.4 ng N spread in the U937 cells. To control for this possibility, mutant
luciferase-encoding reporter viruses with frameshift mutations
in the env gene were tested in the latent cell lines and their
6000000n respective parental cell lines. Luciferase-encoding envelope-
co* deficient (env mutant) viruses were produced in the context of
400000 molecular clones HXB-2 and NL43 (see Materials and Meth-
ods). The availability of two different molecular clones con-
N taining the luciferase gene allowed us to also examine whether
2000000- C"In ~ o H othe patterns of luciferase expression were specific to one
N ° particular molecular clone of HIV. Infection with env mutant
o-w _ HS - _ 4 2 ._reporter viruses pseudotyped with amphotropic envelopeHOSoHOST4 (HXB-LucE - :ampho or NL43-LucE- :ampho viruses) yieldedCELL: HOS HOST4 HOS HOST4 results similar to those obtained with HIV envelope-expressing
VIRUS: HXB Luc HXB Luc HBLuc:ampho HX Luc:ampho virus (HXB-Luc:ampho). Ul cells exhibited a low expression
FIG. 1. Luciferase activity measured 48 h after infection of HOS phenotype compared with the high expression seen in U937
and HOST4 cells with pseudotyped HXB-Luc:amphovirus or non- cells, and ACH-2 cells again displayed a high expression
pseudotyped HXB-Luc virus as indicated. Cells were infected with phenotype with luciferase synthesis consistently higher than
virus supernatants containing the indicated quantity of viral p24 that seen in A3.01 cells (Fig. 3). Thus, the differential ability of
antigen in nanograms. the reporter virus to spread in cell culture did not contribute to
the observed differences in the luciferase expression between
the latent lines and their parental lines.
We have also found that the envelope-expressing luciferase-
relative to U937 throughout the time course (Fig. 2A). This encoding viruses do not spread efficiently in cell culture (data
pattern of low-level expression could not be overcome by the not shown), which most probably explains why the env mutant
use of virus pseudotyped with amphotropic envelope. In viruses do not show a lower luciferase expression in any of the
contrast, the parental cell line, U937, was efficiently infected cell lines. Identical results were obtained with env mutant
with either HXB-Luc or HXB-Luc:ampho as indicated by luciferase-encoding viruses generated from the HXB-2-derived
significant luciferase activity from both viruses as early as 19 to clone, HXB-LucE -, and the NL43-derived clone, NL43-
24 h postinfection. Thus, despite the abrogation of a possible LucE -, indicating that differences in expression are not spe-
superinfection block by using an amphotropic envelope- cific to one molecular clone of HIV (data not shown).
pseudotyped virus, the secondarily introduced virus expressed Activation of latent virus by PMA-PHA in HIV Luc-super-
only very low levels of luciferase in the Ul cells relative to the infected Ul cells. To ascertain whether superinfected HIV-Luc
U937 cells. In the Ul cells it must be either the presence of an in Ul cells could be activated in a manner similar to the
inhibitory factor(s) or the absence of an appropriate positive endogenous Ul provirus, we stimulated Ul cells with phorbol
factor(s) which limits virus expression in these cells. Equivalent myristate acetate (PMA)-phytohemagglutinin (PHA) (50
results were obtained in repeated experiments with different ng/ml and 2 ,ug/ml, respectively) 8 days following superinfec-
virus stocks and with Ul and U937 cells obtained from tion with HIV Luc:ampho. After stimulation for 24 h, lucif-
different passage numbers (data not shown). erase expression from stimulated cells was compared with
Proviral latency in ACH-2 is not due to a latent cellular luciferase expression from identically superinfected, unstimu-
phenotype. Like the Ul cells, the ACH-2 cells expressed only lated cells. A dramatic 36-fold induction of luciferase activity
low levels of luciferase when infected with nonpseudotyped was generated by PMA-PHA treatment of superinfected Ul
HXB-Luc (Fig. 2B). In contrast, when ACH-2 cells were (Fig. 4), indicating that the reporter virus can indeed be
infected with an HXB-Luc:ampho virus, levels of luciferase activated from its latent state in a manner similar to that for
expression in the cells were high relative to those in A3.01 cells. the endogenous virus. The induction of luciferase activity in
Luciferase levels in the parental cell line A3.01 indicated that the Ul cells also demonstrates that the low luciferase expres-
these cells could be infected by either HXB-Luc or HXB- sion in the cells was not due to a failure to infect them
Luc:ampho. These data indicate that the ACH-2 cell line has a efficiently. When similarly infected U937 cells were stimulated,
strong superinfection block to HIV which can be overcome by only a modest twofold induction was evident (see Discussion).
the infection with amphotropic envelope, consistent with the Low expression in Ul cells is not due to poor efficiency of
previously reported low CD4 expression (14). However, the entry or reverse transcription. To monitor the efficiency of
cellular environment of ACH-2 is highly permissive for HIV amphotropic envelope-mediated infection, we harvested cellu-
growth, implying that the defect responsible for the quiescence lar DNA from the latently infected cells and their respective
of the endogenous provirus must be the consequence of a parental lines 72 h after infection with NL43-LucE-:ampho
cis-acting effect. The high expression in ACH-2 relative to that virus. All virus stocks used for experiments involving PCR were
in A3.01 suggests that ACH-2 cells may be primed for high treated with 15 ,ug of bovine pancreatic DNase per ml for 45
HIV expression, perhaps owing to preexisting HIV regulatory min at 37°C in the presence of 10 mM MgC12 prior to infection
proteins or, alternatively, to clonal variation between the to degrade any plasmid DNA contaminating the stock. Infec-
ACH-2 cells and parental cell line, A3.01. Again, equivalent tion with NL43-LucE-:ampho gave rise to the same pattern of
results were obtained in repeated experiments with different low expression in Ul cells relative to U937 cells and to high
virus stocks and ACH-2 and A3.01 cells of different passage expression in ACH-2 cells relative to A3.01 cells (data not
number (data not shown). shown). Cells infected with heat-inactivated virus (15 min at
Higher viral expression in U937 cells is not due to more 65°C) showed no luciferase activity (data not shown). Quanti-
efficient viral spread. Because the pseudotyped HXB-Luc: tative PCR was performed on DNA samples with primers
ampho virus contains an intact env gene, it was possible that specific for luciferase (Fig. 5). Ut and U937 DNAs contained
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FIG. 2. (A) Luciferase activity following infection of 4 x 10 Ut or U937 cells with HXB-Luc or HXB-Luc:ampho virus containing 60 ng of
p24 antigen, at successive time points (in hours) following infection (hpi). (B) Luciferase activity following infection of 4 x 106 ACH-2 or A3.01
cells with HXB-Luc or HXB-Luc:ampho virus containing 60 ng of p24, at successive time points following infection. Luciferase numbers shown
in panels A and B correspond to activity measured from cell extracts containing 10 jig of protein.
comparable levels of luciferase DNA (Fig. 5, lanes 1 and 2).
ACH2 and A3.01 DNAs also had similar levels of luciferase
DNA by the PCR assay (lanes 3 and 4). Control infections of
the cell lines with heat-inactivated HXB-Luc:ampho (lanes 5
through 8) showed that the PCR signal was not due to
contamination of plasmid DNAs in the virus preparation and
was dependent on infection with viable virus. Control PCRs
with no DNA added or with mock-infected cellular DNA were
negative for PCR signal (lanes 9 and 10). Tenfold serial
dilutions of pHXB-Luc plasmid into equivalent amounts of
mock-infected cellular DNA show that the signals are in the
linear range of the PCR assay. These results demonstrate that
Ul or ACH-2 cells were infected with efficiencies equal to
those of their respective parental cell lines and that the
observed differences in luciferase expression were not due to
variable efficiency of infection of the cell lines.
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FIG. 3. Luciferase activity measured at indicated time points
(hours) after infection (hpi) of 4 x 10' Ul, U937, ACH-2, or A3.01
cells with envelope-deficient, pseudotyped virus, NL43-LucE- ampho
(60 ng of p24 antigen). Luciferase numbers correspond to activity
measured from cell extract containing 10 ,ug of protein.
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FIG. 4. Luciferase activities from UI and U937 cells 8 days after
infection with NL43-LucE :ampho virus are shown with PMA-PHA
stimulation (50 ng/ml and 2 jig/ml, respectively, for 24 h) and without
stimulation. Fold increase upon stimulation is indicated to the left.
Luciferase numbers correspond to activity measured from cell extract
containing 10 p.g of protein.
DISCUSSION
The UI and ACH-2 cell lines have provided useful models
for investigating the mechanisms of proviral latency and acti-
vation. Our study has revealed that proviral latency in these
two cell lines is controlled by different mechanisms. We found
that the latently infected Ul cells failed to support efficient
expression of a superinfected, luciferase-encoding HIV re-
porter, suggesting that it is the availability of necessary trans-
acting factors in Ul cells which maintains proviral latency in
these cells. U 1 cells may therefore lack some critical factor for
viral expression or, alternatively, express a repressor of viral
expression. In direct contrast, the ACH-2 cell line displayed no
such intrinsic defect in supporting HIV replication. Rather, the
ACH-2 cellular environment appeared to enhance the expres-
sion of the second virus, perhaps as a consequence of preex-
isting basal production of viral regulatory proteins or because
of clonal variation. Proviral latency in ACH-2 cells may thus be
categorized as a cis-acting effect, potentially a result of an
unfavorable site of integration or hypermethylation (4) of the
proviral DNA. This mode of latency in ACH-2 cells is also
supported by a recent study by Winslow et al., who found high
expression of a secondarily introduced provirus, but not of the
endogenous one, in neomycin-selected ACH-2 cells following
superinfection with a virus carrying a neomycin phosphotrans-
ferase gene (41).
Early data showed that even in patients with AIDS, only a
very small fraction of peripheral blood mononuclear cells
produce significant levels of HIV mRNA (20), a fraction
believed to be significantly smaller than the number of DNA-
positive cells (38). These findings were supported by subse-
quent studies which showed that a pool of latently infected
cells does exist in infected patients (6, 37, 39). In recent work
with sensitive in situ PCR techniques capable of quantifying
single-copy HIV-infected cells, a larger number of latently
infected cells have been detected in both peripheral blood and
the lymph nodes than was previously estimated (11, 12, 30).
While studying HIV-infected chimpanzees as a potential
model for clinical latency of HIV disease, we recently demon-
strated that unstimulated peripheral blood mononuclear cells
from these animals do not show any detectable signs of viral
replication yet can be rapidly induced to express viral mRNAs
after exposure to PMA-PHA in vitro (36). Given such similar-
ities to cells which exist in vivo, it is possible that the mecha-
nisms of latency used by Ul and ACH-2 play a role in HIV
infection of cells in vivo. On the other hand, irrespective of
1 2 3 4 5 6 7 8 9 10 11 12 13 14
FIG. 5. Quantitative DNA PCR with luciferase-specific primers on
500 ng of cellular DNAs prepared from latently infected cell lines and
their parental cell lines 72 h after infection with NL43-LucE :ampho.
UI, U937, ACH-2, or A3.01 cells (106 cells) in 250 pul were infected
with DNase-treated virus containing 200 ng of p24. Lanes: 1 to 4, PCR
products produced from total DNA prepared from infected Ul, U937,
ACH-2, and A3.01 cells, respectively; 5 to 8, PCR products from the
same cell lines infected with heat-treated NL43-LucE- :ampho; 9,
PCR without DNA; 10, mock-infected A3.01 DNA; 11 to 14, standards
containing 500 ng of mock-infected cellular DNAs with 0, 10, 100, and
1,000 fg of pHXB-Luc plasmid DNA.
whether Ul and ACH-2 cells have direct in vivo counterparts,
these cell lines pose interesting questions and should be useful
models for the study of proviral regulation. Hence further
investigation of the mechanisms of viral regulation in these
models of cellular latency seems warranted.
Because of its potential to yield new insights into the cellular
factors that regulate basal HIV expression, it is especially
intriguing to speculate about the nature of the trans-acting
defect found in the UI cells. The SpI- and NF-KB-binding sites
have long been understood to be elements critical for HIV long
terminal repeat activity (18, 21, 29). Spl site-binding proteins
are believed to be involved in the basal transcription of the
HIV long terminal repeat; therefore one might speculate that
differences in Spl site-binding proteins may be involved in the
maintenance of proviral quiescence in the Ul cells. However,
electrophoretic mobility shift assays with Spl site-containing
probes and nuclear extracts from the Ul and U937 cells have
not revealed any qualitative or quantitative differences in the
protein complexes interacting with these sites (8).
Activation of transcription in U1 cells has been correlated
with an increase in NF-KB DNA-binding activity (19). Chronic
HIV infection of certain human myeloid/monocytic cell lines,
including U937, has been found to induce increased nuclear
NF-KB activity even in the absence of any exogenous regula-
tory stimuli (3, 35). Interestingly, although Ul cells are derived
from chronically infected U937 cells, their basal level of NF-KB
activity does not appear to be upregulated, because they show
only weak nuclear NF-KB-binding activity similar to that of
uninfected, unstimulated U937 cells (8, 33). Furthermore,
PMA treatment of the HXB-Luc-superinfected Ul cells in-
duced a 36-fold stimulation in the luciferase activity, whereas
only a 2-fold stimulation was observed in the similarly infected
U937 cells, suggesting that, in the latter, HIV infection may
have already resulted in a near-maximal NF-KB induction.
Thus, a lack of such HIV-induced NF-KB activity could be one
mechanism which restricts the viral replication in Ul cells.
Although the trans-acting mechanism of latency in Ul cells
may draw more experimental attention because of the interest
in identifying the critical trans-acting factors necessary for HIV
expression, it seems equally likely that the cis-acting effect
J. VIROL.
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found in ACH-2 cells could be used in cells in vivo. ACH-2
provides an interesting case in which cellular activation can
overcome a cis-acting inhibitory effect and suggests that differ-
ences in the site of proviral integration can have a critical effect
on the level of viral expression in the absence of activating
stimuli. Such cis-acting mechanisms could be important in vivo
where a suboptimal site of integration may limit viral expres-
sion to a level below a critical threshold level yet still permit
viral upregulation by cellular activation.
In future studies, it will be interesting to test other latently
infected cell lines to see whether the patterns revealed in U1
and ACH-2 may be generalized according to cell type. Addi-
tionally, characterization of other latently infected cell lines
with trans-acting, Ul-like defects may eventually lead to the
identification of new cellular factors that are critical for
regulation of HIV gene expression.
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